Clinical Trial Update: A Study of Safety, Tolerability and Immunogenicity of a 1-Dose Regimen of MRKAd5 HIV-1 Gag Vaccine Versus the ALVAC_HIV Vaccine (V520-019) [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating safety, tolerability and immunogenicity of MRKAd5 HIV-1 Gag Vaccine compared with ALVAC-HIV Vaccine (V520-019); the study is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• ALVAC-HIV Vaccine (V520-019) (ALVAC-based HIV vaccine)
• MRKAd5 HIV-1 Gag Vaccine (Adenovirus 5 vector-based HIV-1 Gag vaccine)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: HIV-1 Infection | Phase 1 | Status: COMPLETED